CClinicalTrials.gg
CompletedNCT03768908ACOIIUpdated Dec 7, 2018

Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005

A Phase 4 interventional study of Artemether-lumefantrine and Artesunate + Amodiaquine in Plasmodium Falciparum Malaria, sponsored by Professor Anders Björkman. Completed. Open to participants aged Up to 60 Months. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Professor Anders Björkman · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 13 years 10 months after the study started (first participant enrolled Jan 2005, registered Dec 2018).
Phase
Phase 4
Study type
Interventional
Enrollment
359
Allocation
Randomized
Ages
Up to 60 Months
Sex
All
01

Study summary

The primary objective of the study was to determine the PCR-APCR up to day 42 in children \<60 months of age, weighing ≥5kg with uncomplicated malaria, treated with either artesunate+ amodiaquine (ASAQ) or artemether-lumefantrine (AL; Coartem®).

Secondary objectives included: clinical and laboratory assessment of drug tolerability and safety, evaluation of possible correlation between drug bioavailability and clinical outcome, comparison of efficacy data with the pre-implementation "ACO I" study, parasite and fever clearance, gametocyte carriage, and possible selection of mutations related to quinoline resistance.

Read the detailed description

All children in the right age group presenting with clinical signs of malaria at the study site were considered possible study subjects. The guardians of these children were informed about the study orally in Swahili according to the informed consent form. Those who were not willing to participate in the study were treated according to local standard procedure.

On day 0 the patient was tested for parasites using light microscopy on Giemsa stained blood films. A detailed clinical history and a clinical examination including an axillary temperature was assessed. Haemoglobin was assessed and blood samples were collected on filter paper for each child for genotyping of the parasites as well as for possible determination of blood levels of different antimalarial drugs.

The guardian was asked to bring their child back to the study site on day 1, 2, 3, 7, 14, 21, 28, 35 and 42. If they failed to do so they were visited in their homes to assure proper follow-up. At each follow-up the investigator asked about concomitant medication and adverse events, carefully filling out the clinical report form (CRF).

If, during the follow-up between day 14 and 42, a child previously enrolled in the study presented with fever, all tests and examinations were run as on day 0. If the child was clinically and parasitologically diagnosed with malaria again, he was treated as a new infection. If diagnosed with severe malaria during the follow-up period the patient was given rescue treatment (oral or intravenous Quinine) and withdrawn from the study. Each time an enrolled child presented at the site the CRF was completed with regards to clinical and laboratory status, treatment given and possible adverse events.

Clinical and laboratory assessments included:

Malaria smear: Giemsa stained thick blood films examined using electrical or sunlight microscope at the study site by an experienced microscopist. The number of parasites were calculated as the number of parasites seen against 200 leucocytes in the thick blood film and recorded in the CRF for the correct occasion. The slides were stored for quality controls double-check (10% of all slides) centrally.

Haemoglobin: Haemoglobin levels were measured by the HaemoCue™ method using blood samples collected on cuvettes. The Hb levels were recorded in the CRF for each occasion.

Full Blood Picture (FBP) and Liver Function Test (LFT): FBP and LFT were performed in the Kivunge Study Site sub-population only (GLP Sub Study). FBP was obtained using the Cell-Dyn 1700™ Haematology Analyser (Abbott Laboratories, USA). LFT, including ALT, AST, Gamma-GT, albumin and bilirubin, was obtained using the BTS-310™ Photometer UV-VIS (BioSystems, Spain).

Temperature and Clinical history: A medical doctor/officer measured the patient's axillary temperature using an electronic thermometer and took a detailed clinical history as well as performed a clinical examination.

PCR Filter paper sample: Blood samples were collected on Whatman FTA filter papers. When dry, each filter paper sample was stored in separate plastic bags at -20ºC (Kivunge) or +4ºC (Micheweni) until regularly transferred to Kivunge for -20ºC long term storage.

HPLC samples (Kivunge only): Approximately 5ml of venous blood was drawn from each patient on days 0 and 7 for FBP and LFT tests. In the ASAQ group 100 µl of this blood was collected on special filter papers for high pressure liquid chromatography (HPLC) analysis of amodiaquine levels. In the AL group 100 µl of plasma (separated by centrifugation at >3000rpm for 10min) was collected on special filter papers for HPLC analysis of lumefantrine levels. All remaining (minimum 2ml) of plasma was collected and kept at -20ºC as a back-up.

Molecular analyses: PCR genotyping of merozoite surface protein 2 (msp2), considered the most informative single genetic marker for multiplicity of P. falciparum infections, was performed to differentiate reinfections from true recrudescence. Paired PCR results were compared between day 0 and at the time of recurrent parasitaemia from day 14 up to day 42. The outer conserved region of the polymorphic repetitive block 3 of msp2 was amplified in an initial reaction followed by two nested reactions with oligonucleotide primers specific for the two allelic families FC27 and IC/3D7, using a standard protocol. The pfmdr1 Y86N and pfcrt K76T genes' Single Nucleotide Proteins (SNPs) analysis was done according to established AluI restriction-based PCR-RFLP protocols. All molecular analyses were performed at the Malaria Research Unit, KI, Sweden.

02

Conditions studied

  • Plasmodium Falciparum Malaria

Keywords

  • Artemether-Lumefantrine
  • Coartem
  • Artesunate
  • Amodiaquine
  • Zanzibar
03

In context

Malaria

1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.

This study's enrollment of 359 is above the median of 220 across 1,027 interventional studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

Professor Anders Björkman is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 60 Months
Sexes eligible
All

Inclusion criteria

  • Weight ≥5kg
  • No general danger signs or severe malaria present (see 4.4.2.1 \& 4.4.2.2)
  • History of fever within 24 hours OR axillary temperature ≥ 37.5Cº
  • No other cause of fever is detectable
  • No severe malnutrition
  • Patient has parasite counts between 2000-200,000/ul (50-5000/200 white blood cells)
  • Guardian/Patient has understood the procedures of the study and is willing to participate
  • Patient able to come for stipulated follow up visits and has easy access to the Study Site

Exclusion criteria

Exclusion Criteria:

General Danger Signs and Complications:

  • Not able to drink or breastfeed
  • Vomiting everything
  • Recent history of convulsions
  • Lethargic or unconscious
  • Unable to sit or stand (as appropriate for age)
  • History of allergy to test drugs
  • History of intake of any drugs other than paracetamol and aspirin within 3 days

Signs of Severe Malaria:

  • Altered consciousness
  • Repeated convulsions
  • Inability of oral intake
  • Severe anaemia (Hb \<5gm/dl)
  • Difficulty in breathing (pulmonary oedema, Respiratory Distress Syndrome)
  • Shock (small pulse, cold extremities)
  • Hypoglycaemia
  • Haemoglobinuria (dark coloured urine or Coca-Cola urine)
  • Kidney failure (little or no urine in a well-hydrated patient)
  • Jaundice (yellow colouring of eyes)
  • Hyperpyrexia (temperature above 39.5ºC) in combination with other signs
  • Hyperparasitaemia (more than 5% red blood cells parasitized or >200,000 parasites/µl)
  • Spontaneous bleeding (Disseminated Intravascular Coagulation)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
359 participants (actual)

Study arms

  • Active comparator
    Treatment with artesunate + amodiaquine

    Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children \<12months \<10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.

    Drug: Artesunate + Amodiaquine

  • Active comparator
    Treatment with artemether-lumefantrine (Coartem®)

    Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children \<60 months, 5-14kg: 1 tab/dose; Children \<60 months \>14kg: 2 tabs/dose.

    Drug: Artemether-lumefantrine

Interventions

  • DrugArtemether-lumefantrine

    Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation

    Also known as: Coartem®

  • DrugArtesunate + Amodiaquine

    Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation

    Also known as: ASAQ

06

What researchers measure

Primary outcomes

  1. PCR adjusted parasitological cure rates by day 42

    Comparing PCR adjusted parasitological cure rate (PCR-APCR) between the two treatment options up to day 42. Parasitological cure will be adjusted using PCR genotyping of msp2 marker. Recrudescence is defined as the presence of at least one matching allelic band, and reinfection as the absence of any matching allelic band on day 0 and day of recurring parasitaemia. Patients with recurrent parasitaemia having missing filter paper sample or negative PCR results will be considered uncertain with regards to PCR adjusted outcome.

    Time frame: 42 days

Secondary outcomes

  1. The clinical and parasitological response outcome (i.e. cure rates) on days 14, day 28 and 42.

    Comparing proportion of response outcomes according to standard WHO classification i.e., cure rates on days 14, day 28 and 42. Defined as the absence of both re-parasitaemia and clinical symptoms suggestive of severe malaria during follow-up to the respective days.

    Time frame: 42 days

Other outcomes

  1. Clinical and laboratory assessment of drug tolerability and safety i.e., incidence of adverse events.

    Proportion of patients reporting any adverse event (AE) in the two study arms. The intensity of an adverse event was determined according to the following definitions: mild, moderate, severe, unknown. AEs were be categorized according to if there is a likely causal relationship between the event and the medical products: probably, possibly, unlikely.

    Time frame: 42 days

  2. Fever clearance in the two study arms

    Fever clearance was determined by a medical doctor/officer who measured the patient's axillary temperature using an electronic thermometer and took a detailed clinical history as well as performed a clinical examination. All details were recorded in the CRF.

    Time frame: 42 days

  3. Parasite clearance and gametocyte carriage in the two study arms

    Clearance of parasites and gametocyte carriage were determined by Giemsa stained thick blood films were examined using electrical or sunlight microscope at the study site by an experienced microscopist. The number of parasites were calculated as the number of parasites seen against 200 leucocytes in the thick blood film and recorded in the CRF for the correct occasion. The slides were stored for quality controls, 10% of all slides were double-checked centrally.

    Time frame: 42 days

  4. Proportion of mutations related to Quinoline resistance at day0 and day of recurrent infection in the two study arms

    Proportions of single nucleotide polymorphisms at pfmdr1 Y86N and pfcrt K76T determined by established AluI restriction-based PCR-RFLP.

    Time frame: 42 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007 Sep;7(5):562-9. doi: 10.1016/j.meegid.2007.03.005. Epub 2007 Mar 31. PubMed 17467344 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03768908
Lead sponsor
Professor Anders Björkman
Collaborators
Zanzibar Malaria Control Programme
Responsible party
Professor Anders Björkman (Professor, Karolinska Institutet) — Sponsor-investigator
First posted
Dec 7, 2018
Start date
Jan 5, 2005
Primary completion
Jul 11, 2005
Completion
Jul 11, 2005
Last update
Dec 7, 2018

Study contacts

Johan Stromberg
principal investigator · Karolinska Institutet
Mwinyi I Msellem
Zanzibar Malaria Control Programme
Andreas Martensson
Karolinska Institutet

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion